Teva Pharmaceutical Industries (TEVA) US affiliate Teva Pharmaceuticals said Friday that TEV-'749 showed significant improvement in social functioning and quality of life at week eight in adult patients with schizophrenia.
The data is from the acute treatment portion of the phase 3 clinical subcutaneous olanzapine extended-release injection study, according to the company.
The company said no new safety signals for drug delivery method were identified and no post-injection delirium/sedation syndrome events were reported.
Interim results for a phase 1 trial show that the drug delivery method may help prevent the development of post-injection delirium/sedation syndrome, Teva added.
Price: 18.49, Change: +0.05, Percent Change: +0.27
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。